BCDA Share Price Performance
US$1.20
-1.35 (-52.94%)
92.3% undervalued intrinsic discount
US$15.50
Fair Value
Price US$1.20
AnalystConsensusTarget US$15.50
AnalystLowTarget US$6.00
Fair ValueUS$15.50
Share Pricen/a
BioCardia, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
BCDA Community Narratives
AN
Fair Value US$15.5 92.3% undervalued intrinsic discount
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$6 80.0% undervalued intrinsic discount
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
Catalysts About BioCardia BioCardia develops cell and biotherapeutic delivery therapies aimed at treating cardiovascular disease. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$15.5
92.3% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
319x
Price in 2029
US$0
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
Catalysts About BioCardia BioCardia develops cell therapies and delivery systems for cardiovascular diseases, focusing on heart failure and ischemic heart conditions. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$6
80.0% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
97.15x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Aging Heart Failure Trends And Cell Therapies Will Reshape This Cardiovascular Pipeline
Fair Value: US$15.5 92.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory And Trial Setbacks Will Dominate Before Long Term Cardiac Therapies Pay Off
Fair Value: US$6 80.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
BioCardia, Inc. Key Details
About BCDA
- Founded
- n/a
- Employees
- 19
- CEO
- WebsiteView website
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company’s lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. It also has a development and commercialization agreement with CART-Tech, B.V. for the development of Heart3D Fusion Imaging system. BioCardia, Inc. is based in Sunnyvale, California.
